

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
Assistant Commissioner For Patents
Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of Paul L. Kaufman and Benjamin Geiger for **CYTOSKELETAL ACTIVE AGENTS FOR GLAUCOMA THERAPY**.

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the U.S. Postal Service on this date **February 11, 1998** in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number **EM 121 691 975 US** addressed to: **Box Patent Application**, Assistant Commissioner For Patents, Washington, D.C. 20231.


Marlene E. Garitano

1. **Type Of Application**
This new application is for a(n)
☒ Original (nonprovisional).
☒ Continuation.
2. **Benefit Of Prior U.S. Application(s)** (35 U.S.C. §§ 119(e), 120, or 121)
☒ The new application being transmitted claims the benefit of prior U.S. application(s) and enclosed are **ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED**.
3. **Papers Enclosed That Are Required For Filing Date Under 37 C.F.R. § 1.53(b) (Regular) or 37 C.F.R. § 1.153 (Design) Application**
66 Pages of Specification;
3 Pages of Claims;
1 Page of Abstract; and
14 Sheets of Informal Drawings.
4. **Additional Papers Enclosed**
☒ Preliminary Amendment; and
☒ Declarations of Drs. Paul L. Kaufman and Thomas Mittag.
5. **Declaration**
☒ Enclosed.
☒ Unexecuted. An executed Declaration will follow.
6. **Inventorship Statement**
The inventorship for all the claims in this application is:
☒ the same.
7. **Language**
☒ English.
8. **Assignment**
☒ An Assignment of the invention to **Wisconsin Alumni Research Foundation** is attached.
☒ Unexecuted. An executed Assignment and Form PTO-1595 will follow.

9. Fee Calculation (37 C.F.R. § 1.16)

☒ Regular application.

CLAIMS AS FILED

Number Filed	Number Extra	Rate	Basic Fee - \$790.00 (37 C.F.R. § 1.16(a))
Total Claims (37 C.F.R. § 1.16(c))	13 - 20 =	0 × \$22.00 =	\$0.00
Independent Claims (37 C.F.R. § 1.16(b))	3 - 3 =	0 × \$82.00 =	\$0.00
Multiple Dependent Claim(s), if any (37 C.F.R. § 1.16(d))	+ \$270.00 =		\$0.00
Filing Fee Calculation			\$790.00

☒ Preliminary Amendment cancelling extra claims enclosed.

10. Fee Payment Being Made At This Time

☒ Enclosed.

☒ basic filing fee

\$790.00

Total Fees Enclosed

\$790.00

11. Method of Payment of Fees

☒ Check in the amount of \$790.00

12. Authorization To Charge Additional Fees and Credit Overpayment

☒ The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No.: 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

13. Power of Attorney by Assignee


☒ Enclosed.

☒ Unexecuted. An executed Power of Attorney will follow.

14. Return Receipt Postcard

☒ Enclosed.

Dated: February 11, 1998


Kamrin T. MacKnight
Registration No.: 38,230

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
(415) 705-8410

☒ Incorporation By Reference Of Added Pages

☒ Plus Added Pages For New Application Transmittal Where Benefit Of Prior U.S. Application(s)
Claimed

Number of pages added: 1

ADDED PAGES FOR APPLICATION TRANSMITTAL
WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED

15. Relate Back

A. 35 U.S.C. §§ 120, 121 and 365(c)

- ☒ Amend the Specification by inserting before the first line the sentence:
"This is a Continuation of copending application Serial No. 08/608,568,
filed on 02/21/96."

16. Further Inventorship Statement Where Benefit Of Prior Application(s) Claimed

a. This application discloses and claims only subject matter disclosed in the prior application whose particulars are set out above and the inventor(s) in this application are

- ☒ the same.

17. Notification in Parent Application of this Filing

- ☒ A notification of the filing of this

☒ continuation

is being filed in the parent application from which this application claims priority under 35 U.S.C. § 120.